Biomarkers /
NTRK2
Overview
Neurotrophic tyrosine kinase, receptor, type 2 (NTRK2) is a gene that encodes a protein in the neurotrophic tyrosine receptor kinase (NTRK) family that participates in the MAP kinase signaling pathway. Fusions, missense, nonsense, and silent mutations are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.
NTRK2 is altered in 1.43% of all cancers with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, cutaneous melanoma, and melanoma having the greatest prevalence of alterations [3].
The most common alterations in NTRK2 are NTRK2 Mutation (1.25%), NTRK2 Loss (0.04%), NTRK2 Fusion (0.05%), NTRK2 Amplification (0.04%), and NTRK2 V606I (0.04%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of NTRK2 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.